Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7277950 | 0.84 | FAAH (0.45) | — | |
| Oxalic Acid SCHEMBL10558479 | 0.79 | TAAR1 (0.41) | SIGMAR1 | |
| SCHEMBL10453660 | 0.74 | SIGMAR1 (0.91) | SIGMAR1 | |
| SCHEMBL9768701 | 0.74 | SIGMAR1 (0.86) | SIGMAR1 | |
| Oxalic Acid SCHEMBL10560742 | 0.73 | DPP4 (0.42) | SIGMAR1CYP2D6 | |
| SCHEMBL4258936 | 0.73 | KDM4E (0.44) | — | |
| SCHEMBL625373 | 0.72 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL20689719 | 0.72 | SIGMAR1 (0.91) | SIGMAR1 | |
| SCHEMBL7272554 | 0.72 | SIGMAR1 (0.91) | SIGMAR1 | |
| SCHEMBL283735 | 0.72 | SIGMAR1 (0.81) | SIGMAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679406-B | Thiazolyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-07-10 | — | — | CN | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| CN-101679406-A | Thiazolyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2010-03-24 | — | — | CN | disclosed |
| EP-2132203-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008124757-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | TTBK1, ERBB2, TEC | SIGMAR1 3965/4885CYP2D6 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.